Avodart and Hepatotoxicity - a phase IV clinical study of FDA data

Summary:

Hepatotoxicity is reported as a side effect among people who take Avodart (dutasteride), especially for people who are male, 60+ old, also take Tafinlar, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Hepatotoxicity when taking Avodart. It is created by eHealthMe based on reports of 15,537 people who have side effects when taking Avodart from the FDA, and is updated regularly.

What is Avodart?

Avodart has active ingredients of dutasteride. It is often used in prostate examination abnormal. eHealthMe is studying from 16,428 Avodart users. Check the latest studies of Avodart.

What is Hepatotoxicity?

Hepatotoxicity (chemical-driven liver damage) is found to be associated with 1,088 drugs and 1,249 conditions by eHealthMe. Check the latest studies of Hepatotoxicity.

On Jul, 07, 2026

15,537 people reported to have side effects when taking Avodart.
Among them, 15 people (0.1%) have Hepatotoxicity.

Among these 15 people:

What is the gender of people who have Hepatotoxicity when taking Avodart? *

female: 0.0 %
male: 100 %

What is the age of people who have Hepatotoxicity when taking Avodart? *

What are other drugs people take besides Avodart? *

What are other side effects people have besides Hepatotoxicity? *

Weakness: 6 people, 40.00%
Fever: 6 people, 40.00%
Arrhythmias (irregular heartbeat): 4 people, 26.67%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 4 people, 26.67%
Hyperkeratosis (thickening of the outer layer of the skin): 4 people, 26.67%
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 3 people, 20.00%
Weight Decreased: 2 people, 13.33%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 13.33%
Cough: 2 people, 13.33%
Ejection Fraction Decreased (systolic heart failure): 2 people, 13.33%

What are the existing conditions these people have? *

High Blood Cholesterol: 7 people, 46.67%
High Blood Pressure: 6 people, 40.00%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 4 people, 26.67%
Klebsiella Sepsis (klebsiella causes a potentially fatal whole-body inflammation): 3 people, 20.00%
Renal Cancer Metastatic (cancer of kidney spreads to other part): 2 people, 13.33%
Nephropathy (damage to or disease of a kidney): 1 person, 6.67%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 6.67%
Ill-Defined Disorder: 1 person, 6.67%
Glomerulonephritis Chronic (long lasting group of conditions that affect parts of the kidneys called glomeruli): 1 person, 6.67%
Essential Hypertension (primary hypertension): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Avodart and have Hepatotoxicity?

- Check whether Hepatotoxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Avodart:

Avodart (16,428 reports)

Hepatotoxicity treatments and more:

Hepatotoxicity (23,823 reports)

Browse all side effects of Avodart:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatotoxicity:

Hepatotoxicity (1,088 drugs)

Browse all the conditions that are associated with Hepatotoxicity:

Hepatotoxicity (1,249 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dutasteride (the active ingredients of Avodart) and Avodart (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.